Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Micardis
Micardis 20 mg tablets Micardis 40 mg tablets Micardis 80 mg tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-089049 · Präparat HOS-083769
Potassium sparing diuretics or potassium supplements
Angiotensin II receptor blockers such as telmisartan, attenuate diuretic induced potassium loss.
Potassium sparing diuretics e.g. spirinolactone, eplerenone, triamterene, or amiloride, potassium
supplements, or potassium-containing salt substitutes may lead to a significant increase in serum
potassium. If concomitant use is indicated because of documented hypokalaemia, they should be used
with caution and with frequent monitoring of serum potassium.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): angiotensin II (HOS-085480) amiloride (HOS-089052) triamterene (HOS-089051) eplerenone (HOS-089050) lead (HOS-085592) potassium (HOS-086929)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-17T14:21:00Z · SHA-256 0a398482ddd47534a4304565ae9e2ee9e7377ec0d61f91d44ea22c7544561f30 · Passage 2d8199debaef64eb82d71ba20563db257ef48ed20e42a5318dce8c03e918085e · Zeichen 1327–1833 im Abschnitt
Gegenanzeigen · Vfend
VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 5–6
HOS-109427 · Präparat HOS-093201
5
• Sirolimus
• Naloxegol
• Tolvaptan
• Finerenone
• Eplerenone
• Voclosporin
• Venetoclax: Coadministration contraindicated at initiation and during venetoclax dose titration
phase.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): eplerenone (HOS-089050) finerenone (HOS-109430) tolvaptan (HOS-109429) venetoclax (HOS-086143) naloxegol (HOS-109428) sirolimus (HOS-085172) voclosporin (HOS-109432)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 8b0d27d100c4cc901857187992d955e0050c45a60166ea142763ba82a6766fef · Zeichen 782–1039 im Abschnitt
Gegenanzeigen · Vfend
VFEND 200 mg powder for solution for infusion · Abschnitt 4.3 · PDF-Seite 36
HOS-109524 · Präparat HOS-093201
• Terfenadine
• Astemizole
• Cisapride
• Pimozide
• Lurasidone
• Quinidine
• Ivabradine
• Ergot alkaloids (e.g., ergotamine, dihydroergotamine)
• Sirolimus
• Naloxegol
• Tolvaptan
• Finerenone
• Eplerenone
• Voclosporin
• Venetoclax: Coadministration contraindicated at initiation and during venetoclax dose titration
phase.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) eplerenone (HOS-089050) quinidine (HOS-085593) finerenone (HOS-109430) tolvaptan (HOS-109429) ergot alkaloids (HOS-108807) venetoclax (HOS-086143) naloxegol (HOS-109428) ivabradine (HOS-109426) pimozide (HOS-085600) astemizole (HOS-085608) sirolimus (HOS-085172) voclosporin (HOS-109432) ergotamine (HOS-086154) terfenadine (HOS-085607) lurasidone (HOS-086148) dihydroergotamine (HOS-086152)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 392392b9fe6da7258d9d0da5625b43e73df89387373d420d8ae08c8a730299d2 · Zeichen 515–979 im Abschnitt
Gegenanzeigen · Vfend
VFEND 40 mg/ml powder for oral suspension · Abschnitt 4.3 · PDF-Seite 69
HOS-109587 · Präparat HOS-093201
• Terfenadine
• Astemizole
• Cisapride
• Pimozide
• Lurasidone
• Quinidine
• Ivabradine
• Ergot alkaloids (e.g., ergotamine, dihydroergotamine)
• Sirolimus
• Naloxegol
• Tolvaptan
• Finerenone
• Eplerenone
• Voclosporin
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) eplerenone (HOS-089050) quinidine (HOS-085593) finerenone (HOS-109430) tolvaptan (HOS-109429) ergot alkaloids (HOS-108807) naloxegol (HOS-109428) ivabradine (HOS-109426) pimozide (HOS-085600) astemizole (HOS-085608) sirolimus (HOS-085172) voclosporin (HOS-109432) ergotamine (HOS-086154) terfenadine (HOS-085607) lurasidone (HOS-086148) dihydroergotamine (HOS-086152)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 52e206f10d0171fc7c859121398e23adfe815eb2cdb7b4fd04fb205bc3c3bde3 · Zeichen 515–854 im Abschnitt
Wechselwirkungen · Vfend
VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 16–17
HOS-109484 · Präparat HOS-093201
16
Non-steroidal selective mineralocorticoid receptor (MR) antagonists
Finerenone Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
finerenone.
Eplerenone Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
eplerenone.
Non-steroidal anti-inflammatory drugs (NSAIDs)
[CYP2C9 substrates] Frequent monitoring for adverse
S-Ibuprofen Cmax 20% reactions and toxicity related to
Ibuprofen (400 mg single dose) S-Ibuprofen AUC0- 100% NSAIDs is recommended. Dose
reduction of NSAIDs may be
Diclofenac (50 mg single dose) Diclofenac Cmax 114% needed.
Diclofenac AUC0- 78%
Opioids
Long-Acting Opiates In an independent published study, Dose reduction in oxycodone and
[CYP3A4 substrates] Oxycodone Cmax 1.7-fold other long-acting opiates
Oxycodone AUC0- 3.6-fold metabolised by CYP3A4
Oxycodone (10 mg single (e.g., hydrocodone) should be
dose) considered. Frequent monitoring
for opiate-associated adverse
reactions may be necessary.
Methadone (32-100 mg QD) R-methadone (active) Cmax 31% Frequent monitoring for adverse
[CYP3A4 substrate] R-methadone (active) AUC 47% reactions and toxicity related to
S-methadone Cmax 65% methadone, including QTc
S-methadone AUC 103% prolongation, is recommended.
Dose reduction of methadone
may be needed.
Short-acting Opiates Dose reduction of alfentanil,
[CYP3A4 substrates] fentanyl and other short-acting
opiates similar in structure to
Alfentanil (20 μg/kg single In an independent published study, alfentanil and metabolised by
dose, with concomitant Alfentanil AUC0- 6-fold CYP3A4 (e.g., sufentanil) should
naloxone) be considered. Extended and
frequent monitoring for
Fentanyl (5 g/kg single dose) In an independent published study, respiratory depression and other
Fentanyl AUC0- 1.34-fold opiate-associated adverse
reactions is recommended.
Opioid receptor antagonists
Naloxegol Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
naloxegol.
Oral contraceptives
Oral Contraceptives* Ethinylestradiol Cmax 36% Monitoring for adverse reactions
[CYP3A4 substrate; CYP2C19 Ethinylestradiol AUC 61% related to oral contraceptives, in
inhibitor] Norethisterone Cmax 15% addition to those for
Norethisterone/ethinylestradiol Norethisterone AUC 53% voriconazole, is recommended.
(1 mg/0.035 mg QD) Voriconazole Cmax 14%
Voriconazole AUC 46%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) diclofenac (HOS-085903) ibuprofen (HOS-087884) methadone (HOS-086198) eplerenone (HOS-089050) oxycodone (HOS-109487) finerenone (HOS-109430) naloxegol (HOS-109428) hydrocodone (HOS-109488) naloxone (HOS-109490) fentanyl (HOS-086196) sufentanil (HOS-109489)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 8ddbb18c489ccc11c6814ac36e2fb24fd816c63d5b15490877a83dbf46e7d7f5 · Zeichen 27474–31780 im Abschnitt
Wechselwirkungen · Vfend
VFEND 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 48–49
HOS-109554 · Präparat HOS-093201
48
Non-steroidal selective mineralocorticoid receptor (MR) antagonists
Finerenone Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
finerenone.
Eplerenone Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
eplerenone.
Non-steroidal anti-inflammatory drugs (NSAIDs)
[CYP2C9 substrates] Frequent monitoring for adverse
S-Ibuprofen Cmax 20% reactions and toxicity related to
Ibuprofen (400 mg single dose) S-Ibuprofen AUC0- 100% NSAIDs is recommended. Dose
reduction of NSAIDs may be
Diclofenac (50 mg single dose) Diclofenac Cmax 114% needed.
Diclofenac AUC0- 78%
Opioids
Long-Acting Opiates In an independent published study, Dose reduction in oxycodone and
[CYP3A4 substrates] Oxycodone Cmax 1.7-fold other long-acting opiates
Oxycodone AUC0- 3.6-fold metabolised by CYP3A4
Oxycodone (10 mg single (e.g., hydrocodone) should be
dose) considered. Frequent monitoring
for opiate-associated adverse
reactions may be necessary.
Methadone (32-100 mg QD) R-methadone (active) Cmax 31% Frequent monitoring for adverse
[CYP3A4 substrate] R-methadone (active) AUC 47% reactions and toxicity related to
S-methadone Cmax 65% methadone, including QTc
S-methadone AUC 103% prolongation, is recommended.
Dose reduction of methadone
may be needed.
Short-acting Opiates Dose reduction of alfentanil,
[CYP3A4 substrates] fentanyl and other short-acting
opiates similar in structure to
Alfentanil (20 μg/kg single In an independent published study, alfentanil and metabolised by
dose, with concomitant Alfentanil AUC0- 6-fold CYP3A4 (e.g., sufentanil) should
naloxone) be considered. Extended and
frequent monitoring for
Fentanyl (5 g/kg single dose) In an independent published study, respiratory depression and other
Fentanyl AUC0- 1.34-fold opiate-associated adverse
reactions is recommended.
Opioid receptor antagonists
Naloxegol Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
naloxegol.
Oral contraceptives
Oral Contraceptives* Ethinylestradiol Cmax 36% Monitoring for adverse reactions
[CYP3A4 substrate; CYP2C19 Ethinylestradiol AUC 61% related to oral contraceptives, in
inhibitor] Norethisterone Cmax 15% addition to those for
Norethisterone/ethinylestradiol Norethisterone AUC 53% voriconazole, is recommended.
(1 mg/0.035 mg QD) Voriconazole Cmax 14%
Voriconazole AUC 46%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) diclofenac (HOS-085903) ibuprofen (HOS-087884) methadone (HOS-086198) eplerenone (HOS-089050) oxycodone (HOS-109487) finerenone (HOS-109430) naloxegol (HOS-109428) hydrocodone (HOS-109488) naloxone (HOS-109490) fentanyl (HOS-086196) sufentanil (HOS-109489)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage e6233d476ccce7daca52d1dd2aaaa91e8c3161bd371e92e18ca8a2257625f3c2 · Zeichen 27978–32284 im Abschnitt
Wechselwirkungen · Vfend
VFEND 40 mg/ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 80–81
HOS-109619 · Präparat HOS-093201
80
Non-steroidal selective mineralocorticoid receptor (MR) antagonists
Finerenone Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
finerenone.
Eplerenone Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
eplerenone.
Non-steroidal anti-inflammatory drugs (NSAIDs)
[CYP2C9 substrates] Frequent monitoring for adverse
S-Ibuprofen Cmax 20% reactions and toxicity related to
Ibuprofen (400 mg single dose) S-Ibuprofen AUC0- 100% NSAIDs is recommended. Dose
reduction of NSAIDs may be
Diclofenac (50 mg single dose) Diclofenac Cmax 114% needed.
Diclofenac AUC0- 78%
Opioids
Long-Acting Opiates In an independent published study, Dose reduction in oxycodone and
[CYP3A4 substrates] Oxycodone Cmax 1.7-fold other long-acting opiates
Oxycodone AUC0- 3.6-fold metabolised by CYP3A4
Oxycodone (10 mg single (e.g., hydrocodone) should be
dose) considered. Frequent monitoring
for opiate-associated adverse
reactions may be necessary.
Methadone (32-100 mg QD) R-methadone (active) Cmax 31% Frequent monitoring for adverse
[CYP3A4 substrate] R-methadone (active) AUC 47% reactions and toxicity related to
S-methadone Cmax 65% methadone, including QTc
S-methadone AUC 103% prolongation, is recommended.
Dose reduction of methadone
may be needed.
Short-acting Opiates Dose reduction of alfentanil,
[CYP3A4 substrates] fentanyl and other short-acting
opiates similar in structure to
Alfentanil (20 μg/kg single In an independent published study, alfentanil and metabolised by
dose, with concomitant Alfentanil AUC0- 6-fold CYP3A4 (e.g., sufentanil) should
naloxone) be considered. Extended and
frequent monitoring for
Fentanyl (5 g/kg single dose) In an independent published study, respiratory depression and other
Fentanyl AUC0- 1.34-fold opiate-associated adverse
reactions is recommended.
Opioid receptor antagonists
Naloxegol Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
naloxegol.
Oral contraceptives
Oral Contraceptives* Ethinylestradiol Cmax 36% Monitoring for adverse reactions
[CYP3A4 substrate; CYP2C19 Ethinylestradiol AUC 61% related to oral contraceptives, in
inhibitor] Norethisterone Cmax 15% addition to those for
Norethisterone/ethinylestradiol Norethisterone AUC 53% voriconazole, is recommended.
(1 mg/0.035 mg QD) Voriconazole Cmax 14%
Voriconazole AUC 46%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) diclofenac (HOS-085903) ibuprofen (HOS-087884) methadone (HOS-086198) eplerenone (HOS-089050) oxycodone (HOS-109487) finerenone (HOS-109430) naloxegol (HOS-109428) hydrocodone (HOS-109488) naloxone (HOS-109490) fentanyl (HOS-086196) sufentanil (HOS-109489)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 5c1a7a3fda98976f51693be4906d67df598ab85a4fcf5f8cd51e8c0fe387196a · Zeichen 27504–31810 im Abschnitt
Wechselwirkungen · Telmisartan Actavis
Telmisartan Actavis 20 mg tablets Telmisartan Actavis 40 mg tablets Telmisartan Actavis 80 mg tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-122751 · Präparat HOS-095571
Potassium sparing diuretics or potassium supplements
Angiotensin II receptor antagonists such as telmisartan attenuate diuretic induced potassium loss.
Potassium sparing diuretics e.g. spirinolactone, eplerenone, triamterene, or amiloride, potassium
supplements, or potassium-containing salt substitutes may lead to a significant increase in serum
potassium. If concomitant use is indicated because of documented hypokalaemia, they should be used
with caution and with frequent monitoring of serum potassium.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): angiotensin II (HOS-085480) amiloride (HOS-089052) triamterene (HOS-089051) eplerenone (HOS-089050) lead (HOS-085592) potassium (HOS-086929)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-07T12:26:00Z · SHA-256 a0dc3ae714b52325373063082342e7db3d87cc870354af373b58b5bbf44e95ea · Passage 431050ab8f903052457550aa98b24d608668cb65ad6ba9dc5dd7ccd334fe172b · Zeichen 1385–1893 im Abschnitt
Wechselwirkungen · Tolura
Tolura 40 mg tablets Tolura 80 mg tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-212618 · Präparat HOS-154944
Angiotensin II receptor blockers such as telmisartan, attenuate diuretic induced potassium loss.
Potassium sparing diuretics e.g. spirinolactone, eplerenone, triamterene, or amiloride, potassium
supplements, or potassium-containing salt substitutes may lead to a significant increase in serum
potassium. If concomitant use is indicated because of documented hypokalaemia they should be used
with caution and with frequent monitoring of serum potassium.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): angiotensin II (HOS-085480) amiloride (HOS-089052) triamterene (HOS-089051) eplerenone (HOS-089050) lead (HOS-085592) potassium (HOS-086929)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-08T01:00:00Z · SHA-256 dad9c79716ae2a24deb7c55530dea88c80c9a43e260f817adbd1076d5b234243 · Passage 3716844533d55269093c8f985f96b011215783d27e1df4b946a0dcf686dabd32 · Zeichen 1381–1833 im Abschnitt
Wechselwirkungen · Twynsta
Twynsta 40 mg/5 mg tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-123211 · Präparat HOS-095675
Interactions linked to telmisartan
Concomitant use not recommended
Potassium sparing diuretics or potassium supplements
Angiotensin II receptor blockers such as telmisartan, attenuate diuretic induced potassium loss. Potassium
sparing diuretics e.g. spirinolactone, eplerenone, triamterene, or amiloride, potassium supplements, or
potassium-containing salt substitutes may lead to a significant increase in serum potassium. If
concomitant use is indicated because of documented hypokalaemia, they should be used with caution and
with frequent monitoring of serum potassium.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): angiotensin II (HOS-085480) amiloride (HOS-089052) triamterene (HOS-089051) eplerenone (HOS-089050) lead (HOS-085592) potassium (HOS-086929)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T16:05:00Z · SHA-256 d908f2bfe85214b5b2c692a0e9d420ab084836f3e71cbcc740976fe090f1d7ea · Passage 11e213cc7998df0f7a806a5bb1cc7246b0878a013a4e53969f4b81eecdafa838 · Zeichen 896–1469 im Abschnitt
Wechselwirkungen · Twynsta
Twynsta 40 mg/10 mg tablets · Abschnitt 4.5 · PDF-Seite 25
HOS-123290 · Präparat HOS-095675
Interactions linked to telmisartan
Concomitant use not recommended
Potassium sparing diuretics or potassium supplements
Angiotensin II receptor blockers such as telmisartan, attenuate diuretic induced potassium loss. Potassium
sparing diuretics e.g. spirinolactone, eplerenone, triamterene, or amiloride, potassium supplements, or
potassium-containing salt substitutes may lead to a significant increase in serum potassium. If
concomitant use is indicated because of documented hypokalaemia, they should be used with caution and
with frequent monitoring of serum potassium.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): angiotensin II (HOS-085480) amiloride (HOS-089052) triamterene (HOS-089051) eplerenone (HOS-089050) lead (HOS-085592) potassium (HOS-086929)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T16:05:00Z · SHA-256 d908f2bfe85214b5b2c692a0e9d420ab084836f3e71cbcc740976fe090f1d7ea · Passage 11e213cc7998df0f7a806a5bb1cc7246b0878a013a4e53969f4b81eecdafa838 · Zeichen 896–1469 im Abschnitt
Wechselwirkungen · Twynsta
Twynsta 80 mg/5 mg tablets · Abschnitt 4.5 · PDF-Seite 44
HOS-123365 · Präparat HOS-095675
Interactions linked to telmisartan
Concomitant use not recommended
Potassium sparing diuretics or potassium supplements
Angiotensin II receptor blockers such as telmisartan, attenuate diuretic induced potassium loss. Potassium
sparing diuretics e.g. spirinolactone, eplerenone, triamterene, or amiloride, potassium supplements, or
potassium-containing salt substitutes may lead to a significant increase in serum potassium. If
concomitant use is indicated because of documented hypokalaemia, they should be used with caution and
with frequent monitoring of serum potassium.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): angiotensin II (HOS-085480) amiloride (HOS-089052) triamterene (HOS-089051) eplerenone (HOS-089050) lead (HOS-085592) potassium (HOS-086929)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T16:05:00Z · SHA-256 d908f2bfe85214b5b2c692a0e9d420ab084836f3e71cbcc740976fe090f1d7ea · Passage 11e213cc7998df0f7a806a5bb1cc7246b0878a013a4e53969f4b81eecdafa838 · Zeichen 896–1469 im Abschnitt
Wechselwirkungen · Twynsta
Twynsta 80 mg/10 mg tablets · Abschnitt 4.5 · PDF-Seite 63
HOS-123439 · Präparat HOS-095675
Interactions linked to telmisartan
Concomitant use not recommended
Potassium sparing diuretics or potassium supplements
Angiotensin II receptor blockers such as telmisartan, attenuate diuretic induced potassium loss. Potassium
sparing diuretics e.g. spirinolactone, eplerenone, triamterene, or amiloride, potassium supplements, or
potassium-containing salt substitutes may lead to a significant increase in serum potassium. If
concomitant use is indicated because of documented hypokalaemia, they should be used with caution and
with frequent monitoring of serum potassium.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): angiotensin II (HOS-085480) amiloride (HOS-089052) triamterene (HOS-089051) eplerenone (HOS-089050) lead (HOS-085592) potassium (HOS-086929)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T16:05:00Z · SHA-256 d908f2bfe85214b5b2c692a0e9d420ab084836f3e71cbcc740976fe090f1d7ea · Passage 11e213cc7998df0f7a806a5bb1cc7246b0878a013a4e53969f4b81eecdafa838 · Zeichen 896–1469 im Abschnitt
Wechselwirkungen · Telmisartan Teva Pharma
Telmisartan Teva Pharma 20 mg tablets Telmisartan Teva Pharma 40 mg tablets Telmisartan Teva Pharma 80 mg tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-126608 · Präparat HOS-096293
Potassium sparing diuretics or potassium supplements
Angiotensin II receptor antagonists such as telmisartan, attenuate diuretic induced potassium loss. Potassium
sparing diuretics e.g. spironolactone, eplerenone, triamterene, or amiloride, potassium supplements, or
potassium-containing salt substitutes may lead to a significant increase in serum potassium. If concomitant
use is indicated because of documented hypokalaemia, they should be used with caution and with frequent
monitoring of serum potassium.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): angiotensin II (HOS-085480) amiloride (HOS-089052) triamterene (HOS-089051) eplerenone (HOS-089050) lead (HOS-085592) potassium (HOS-086929) spironolactone (HOS-112481)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2021-10-26T17:47:00Z · SHA-256 ef9ae558382f684909b0f21cdb8496614113ed93dd265a52972a82983086dbcb · Passage 9ef3ea0eec6d7f32df4eb56683ec5ccb2cc53ebba6fdcf2cc18045364ce08ff9 · Zeichen 1328–1837 im Abschnitt
Gegenanzeigen · Voriconazole Hikma (previously Voriconazole Hospira)
Voriconazole Hikma 200 mg powder for solution for infusion · Abschnitt 4.3 · PDF-Seite 5–6
HOS-130910 · Präparat HOS-096981
• Terfenadine
• Astemizole
• Cisapride
• Pimozide
• Lurasidone
• Quinidine
5
• Ivabradine
• Ergot alkaloids (e.g., ergotamine, dihydroergotamine)
• Sirolimus
• Naloxegol
• Tolvaptan
• Finerenone
• Eplerenone
• Voclosporin
• Venetoclax: Coadministration contraindicated at initiation and during venetoclax dose titration phase.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) eplerenone (HOS-089050) quinidine (HOS-085593) finerenone (HOS-109430) tolvaptan (HOS-109429) ergot alkaloids (HOS-108807) venetoclax (HOS-086143) naloxegol (HOS-109428) ivabradine (HOS-109426) pimozide (HOS-085600) astemizole (HOS-085608) sirolimus (HOS-085172) voclosporin (HOS-109432) ergotamine (HOS-086154) terfenadine (HOS-085607) lurasidone (HOS-086148) dihydroergotamine (HOS-086152)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-23T14:40:00Z · SHA-256 8f5a567ef9a1f0f0bee27abd2100fc7726dcc5281b72b1f33957fd6bcec22b38 · Passage a6fe4a49e4c7e3e416db9488a60b10861c79e9736141c4f5c1792a87a1df0b1c · Zeichen 509–952 im Abschnitt
Wechselwirkungen · Voriconazole Hikma (previously Voriconazole Hospira)
Voriconazole Hikma 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 17–18
HOS-130968 · Präparat HOS-096981
17
Finerenone Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
finerenone.
Eplerenone Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
eplerenone.
Non-steroidal anti-inflammatory drugs (NSAIDs)
[CYP2C9 substrates] Frequent monitoring for adverse
S-Ibuprofen Cmax ↑ 20% reactions and toxicity related to
Ibuprofen (400 mg single dose) S-Ibuprofen AUC0-∞ ↑ 100% NSAIDs is recommended. Dose
reduction of NSAIDs may be
Diclofenac (50 mg single dose) Diclofenac Cmax ↑ 114% needed.
Diclofenac AUC0-∞ ↑ 78%
Opioids
Long-Acting Opiates In an independent published study, Dose reduction in oxycodone and
[CYP3A4 substrates] Oxycodone Cmax ↑ 1.7-fold other long-acting opiates
Oxycodone AUC0-∞ ↑ 3.6-fold metabolised by CYP3A4
Oxycodone (10 mg single (e.g., hydrocodone) should be
dose) considered. Frequent monitoring
for opiate-associated adverse
reactions may be necessary.
Methadone (32-100 mg QD) R-methadone (active) Cmax ↑ 31% Frequent monitoring for adverse
[CYP3A4 substrate] R-methadone (active) AUCτ ↑ 47% reactions and toxicity related to
S-methadone Cmax ↑ 65% methadone, including QTc
S-methadone AUCτ ↑ 103% prolongation, is recommended.
Dose reduction of methadone
may be needed.
Short-acting Opiates Dose reduction of alfentanil,
[CYP3A4 substrates] fentanyl and other short-acting
opiates similar in structure to
Alfentanil (20 μg/kg single In an independent published study, alfentanil and metabolised by
dose, with concomitant Alfentanil AUC0-∞ ↑ 6-fold CYP3A4 (e.g., sufentanil) should
naloxone) be considered. Extended and
frequent monitoring for
Fentanyl (5 µg/kg single dose) In an independent published study, respiratory depression and other
Fentanyl AUC0-∞ ↑ 1.34-fold opiate-associated adverse
reactions is recommended.
Opioid receptor antagonists
Naloxegol Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
naloxegol.
Oral contraceptives
Oral Contraceptives* Ethinylestradiol Cmax ↑ 36% Monitoring for adverse reactions
[CYP3A4 substrate; CYP2C19 Ethinylestradiol AUCτ ↑ 61% related to oral contraceptives, in
inhibitor] Norethisterone Cmax ↑ 15% addition to those for
Norethisterone/ethinylestradiol Norethisterone AUCτ ↑ 53% voriconazole, is recommended.
(1 mg/0.035 mg QD) Voriconazole Cmax ↑ 14%
Voriconazole AUCτ ↑ 46%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) diclofenac (HOS-085903) ibuprofen (HOS-087884) methadone (HOS-086198) eplerenone (HOS-089050) oxycodone (HOS-109487) finerenone (HOS-109430) naloxegol (HOS-109428) hydrocodone (HOS-109488) naloxone (HOS-109490) fentanyl (HOS-086196) sufentanil (HOS-109489)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-23T14:40:00Z · SHA-256 8f5a567ef9a1f0f0bee27abd2100fc7726dcc5281b72b1f33957fd6bcec22b38 · Passage c15a75c62801770f9555f6206fed29c8569fb1a5f9063364f5ddb780efc68271 · Zeichen 27899–32111 im Abschnitt
Gegenanzeigen · Ketoconazole Esteve (previously Ketoconazole HRA)
Ketoconazole Esteve 200 mg tablets · Abschnitt 4.3 · PDF-Seite 4
HOS-132828 · Präparat HOS-097310
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1;
- Hypersensitivity to any imidazole antifungal medicinal product;
- Acute or chronic liver disease and/or if pre-treatment liver enzymes levels are above 2 times the upper
limit of normal (see sections 4.2 and 4.4):
- Pregnancy (see section 4.6);
- Breastfeeding (see section 4.6);
- Congenital or documented acquired QTc prolongation ;
- Concomitant therapy with any of the following medicinal products which may interact and result in
potentially life-threatening adverse reactions (see section 4.5):
o CYP3A4 metabolised HMG-CoA reductase inhibitors (e.g. simvastatin, atorvastatin and
lovastatin) due to an increased risk of skeletal muscle toxicity including rhabdomyolysis;
o eplerenone due to an increased risk of hyperkalemia and hypotension;
o substances that may have their plasma concentrations increased and have QT prolonging potential:
methadone, disopyramide, quinidine, dronedarone, pimozide, sertindole, saquinavir
(saquinavir/ritonavir 1000/100 mg bid), ranolazine, mizolastine, halofantrine;
o dabigatran due to an increased bleeding risk;
o triazolam, oral midazolam and alprazolam due to potential for prolonged or increased sedation and
respiratory depression;
o ergot alkaloids (eg dihydroergotamine, ergometrine (ergonovine), ergotamine and
methylergometrine (methylergonovine) due to an increased risk of ergotism and other serious
vasospastic adverse reactions;
o lurasidone;
o quetiapine due to an increased risk of toxicity;
o telithromycin and clarithromycin in patients with severe renal impairment due to an increased risk
of hepatotoxicity and QT interval prolongation;
o felodipine, nisoldipine due to an increased risk of oedema and congestive heart failure;
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) quetiapine (HOS-086150) methylergonovine (HOS-086155) dronedarone (HOS-086144) methadone (HOS-086198) lovastatin (HOS-086157) eplerenone (HOS-089050) atorvastatin (HOS-086304) felodipine (HOS-108908) alprazolam (HOS-086171) halofantrine (HOS-085606) simvastatin (HOS-086158) quinidine (HOS-085593) dabigatran (HOS-112096) ergot alkaloids (HOS-108807) imidazole (HOS-117862) disopyramide (HOS-085595) telithromycin (HOS-084523) saquinavir (HOS-084522) clarithromycin (HOS-084517) pimozide (HOS-085600) nisoldipine (HOS-114251) ergotamine (HOS-086154) ritonavir (HOS-084521) lurasidone (HOS-086148) ranolazine (HOS-086141) ergonovine (HOS-086153) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167) mizolastine (HOS-085609)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-05T12:00:00Z · SHA-256 1463d2e081bcaa454cdfd6129ad3b8e03e3df9233f9d0704cfceba71c89c59b5 · Passage f9d16641f2e5b06b321fa0c79f0dacdfede818d20585398b4d37ddb19dad6a14 · Zeichen 0–2044 im Abschnitt
Wechselwirkungen · Ketoconazole Esteve (previously Ketoconazole HRA)
Ketoconazole Esteve 200 mg tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-132842 · Präparat HOS-097310
o CYP3A4 metabolised HMG-CoA reductase inhibitors (e.g. simvastatin, atorvastatin and lovastatin)
due to an increased risk of skeletal muscle toxicity including rhabdomyolysis;
o eplerenone due to an increased risk of hyperkalemia and hypotension;
o substances that may have their plasma concentrations increased and have QT prolonging potential :
methadone, disopyramide, quinidine, dronedarone, pimozide, sertindole, saquinavir (saquinavir/ritonavir
1000/100 mg bid), ranolazine, mizolastine, halofantrine;
o dabigatran due to an increased bleeding risk;
o triazolam, oral midazolam and alprazolam due to potential for prolonged or increased sedation and
respiratory depression;
o ergot alkaloids (eg dihydroergotamine, ergometrine (ergonovine), ergotamine and methylergometrine
(methylergonovine) due to an increased risk of ergotism and other serious vasospastic adverse
reactionsevents
o lurasidone;
o quetiapine due to an increased risk of toxicity;
o telithromycin and clarithromycin in patients with severe renal impairment due to an increased risk of
hepatotoxicity and QT interval prolongation;
o felodipine, nisoldipine due to an increased risk of oedema and congestive heart failure;
o colchicine in patients with renal impairment due to an increased risk of severe adverse reactions;
o irinotecan due to an alteration of the metabolism of this medicinal product;
o everolimus, sirolimus (also known as rapamycin) due to an increase of the plasma concentrations of
these medicinal products;
o vardenafil in men older than 75-years due to increased risk of adverse reactions
o paritaprevir/ombitasvir (ritonavir) due to increased risk of adverse reactions;
o fesoterodine and solifenacin in patients with renal impairment;
o tolvaptan used for a specific disease called “syndrome of inappropriate antidiuretic hormone
secretion”.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) quetiapine (HOS-086150) solifenacin (HOS-116433) methylergonovine (HOS-086155) dronedarone (HOS-086144) methadone (HOS-086198) lovastatin (HOS-086157) eplerenone (HOS-089050) atorvastatin (HOS-086304) felodipine (HOS-108908) alprazolam (HOS-086171) halofantrine (HOS-085606) simvastatin (HOS-086158) quinidine (HOS-085593) dabigatran (HOS-112096) tolvaptan (HOS-109429) ergot alkaloids (HOS-108807) disopyramide (HOS-085595) telithromycin (HOS-084523) saquinavir (HOS-084522) ombitasvir (HOS-110300) clarithromycin (HOS-084517) pimozide (HOS-085600) nisoldipine (HOS-114251) colchicine (HOS-086147) everolimus (HOS-086310) fesoterodine (HOS-116432) sirolimus (HOS-085172) ergotamine (HOS-086154) ritonavir (HOS-084521) paritaprevir (HOS-110301) lurasidone (HOS-086148) ranolazine (HOS-086141) irinotecan (HOS-112102) ergonovine (HOS-086153) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167) mizolastine (HOS-085609) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-05T12:00:00Z · SHA-256 1463d2e081bcaa454cdfd6129ad3b8e03e3df9233f9d0704cfceba71c89c59b5 · Passage 0b65d259964c6f340994be44a864bad55b31283e3fc412d0d5a47323a792d889 · Zeichen 171–2105 im Abschnitt
Wechselwirkungen · Ketoconazole Esteve (previously Ketoconazole HRA)
Ketoconazole Esteve 200 mg tablets · Abschnitt 4.5 · PDF-Seite 12–13
HOS-132868 · Präparat HOS-097310
12
Medicinal product by Expected effect on drug levels Recommendation for co-
therapeutic area administration
Beta Blockers
Nadolol ↑in plasma concentrations of nadolol Careful monitoring. Dose adjustment
have been observed of nadolol may be required.
Calcium Channel
Blockers
Felodipine AUC: ↑ has been observed Contraindicated due to an increase
Nisoldipine Cmax: ↑ has been observed risk of edema and congestive heart
failure (see section 4.3).
Other dihydropyridines Potential ↑in plasma concentrations of Careful monitoring. Dose adjustment
Verapamil these drugs of dihydropyridines and verapamil
may be required.
Cardiovascular Drugs,
Miscellaneous
Ranolazine Ranolazine: Contraindicated due to the potential
AUC: ↑ 3.0 to 3.9-fold for serious cardiovascular events
including QT prolongation (see
section 4.3).
Bosentan Bosentan: Not recommended due to the
AUC: ↑ 2-fold potential for hepatic toxicity (see
Cmax: ↑ 2-fold section 4.3).
Aliskiren Aliskiren: Careful monitoring.
AUC: ↑ 1.8-fold Dose adjustment of aliskiren may be
required.
Diuretics
Eplerenone Eplerenone: Contraindicated due to the increased
AUC: ↑ 5.5-fold risk of hyperkalaemia and
hypotension (see section 4.3).
Gastrointestinal Drugs
Aprepitant Aprepitant: Careful monitoring.
AUC: ↑ 5-fold Dose adjustment of aprepitant
may be required
Domperidone Domperidone: Not recommended due to an
AUC: ↑ 3.0 fold increased risk in QT prolongation.
Cmax: ↑ 3.0 fold
Naloxegol Naloxegol Not recommended
AUC ↑ 12.9 fold
Cmax ↑ 9.6 fold
Immunosuppressants
Everolimus Everolimus: Contraindicated due to the large
Sirolimus (rapamycin) AUC: ↑ 15.3-fold increase in these medicinal products
Cmax: ↑ 4.1-fold concentrations (see section 4.3).
Sirolimus (rapamycin):
AUC: ↑ 10.9-fold
Cmax: ↑ 4.4-fold
Temsirolimus Temsirolimus: Not recommended unless necessary.
AUC: ↔ Careful monitoring and dose
Cmax: ↔ adjustment of these medicinal
Tacrolimus Ciclesonide active metabolite: products may be required.
Ciclosporine AUC: ↑ 3.5-fold
Budesonide
Ciclesonide Rest of drugs
↑in plasma concentrations of
these drugs have been observed
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): temsirolimus (HOS-117078) eplerenone (HOS-089050) felodipine (HOS-108908) aprepitant (HOS-112506) ciclesonide (HOS-132871) aliskiren (HOS-086927) domperidone (HOS-114656) nadolol (HOS-132869) calcium (HOS-085615) naloxegol (HOS-109428) budesonide (HOS-086332) tacrolimus (HOS-085202) nisoldipine (HOS-114251) everolimus (HOS-086310) sirolimus (HOS-085172) bosentan (HOS-086291) ranolazine (HOS-086141) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-05T12:00:00Z · SHA-256 1463d2e081bcaa454cdfd6129ad3b8e03e3df9233f9d0704cfceba71c89c59b5 · Passage 55c1f47059932c9461c4dbc4909ce69dab602449f5d770f01d87bd752335918f · Zeichen 23587–27472 im Abschnitt
Wechselwirkungen · Entresto
Entresto 24 mg/26 mg film-coated tablets Entresto 49 mg/51 mg film-coated tablets Entresto 97 mg/103 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-134366 · Präparat HOS-097566
Potassium
Concomitant use of potassium-sparing diuretics (triamterene, amiloride), mineralocorticoid
antagonists (e.g. spironolactone, eplerenone), potassium supplements, salt substitutes containing
potassium or other agents (such as heparin) may lead to increases in serum potassium, and to increases
in serum creatinine. Monitoring of serum potassium is recommended if sacubitril/valsartan is
co-administered with these agents (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): amiloride (HOS-089052) triamterene (HOS-089051) eplerenone (HOS-089050) heparin (HOS-086930) creatinine (HOS-086273) lead (HOS-085592) potassium (HOS-086929) spironolactone (HOS-112481)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-13T10:33:00Z · SHA-256 63effd0dd78bf1b11f8cfe5ae77efc68b2653de13ba467bbf4e48289e340b97e · Passage c46a4012a89bd5b8b9347cd185d3d13e7106172929865a5f5a9773f105539131 · Zeichen 2369–2816 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.